Akido Labs Secures $60M to Expand AI-Powered ScopeAI and Tackle Physician Shortage

What You Should Know: 

– Akido Labs, Inc. (“Akido”), an AI and care delivery company dedicated to reimagining healthcare raises $60M in Series B funding led by Oak HC/FT, with participation from Greco, SNR, and existing investors including Y Combinator, Future Communities Capital, Jeff Dean (Chief Scientist, Google DeepMind & Google Research), and the Comprehensive Blood & Cancer Center.

– The investment will be channeled towards expanding the reach and capabilities of Akido’s innovative ScopeAI system, a platform designed to increase clinical capacity and dramatically improve healthcare access.

Addressing the Global Physician Deficit with ScopeAI

The U.S. healthcare system faces a significant challenge: demand for care far outstrips available physician capacity. Americans require over 3 billion doctor visits annually, yet only about 825 million are currently available, leading to long wait times, rushed appointments, and an increase in preventable diseases. Akido aims to address this crisis head-on with ScopeAI.

“We built ScopeAI to tackle the single biggest challenge facing healthcare systems worldwide: the physician shortage,” said Prashant Samant, Co-Founder & CEO of Akido. “With demand for care far exceeding supply, AI is the key to addressing the global doctor deficit, empowering healthcare providers, and ensuring patients receive the timely, high-quality care they deserve, regardless of financial means or geography. At Akido, we believe exceptional healthcare is a basic human right. Our work has always focused on democratizing high quality healthcare, and this funding enables us to accelerate that mission.”

ScopeAI is transforming how Akido providers practice medicine by embedding powerful medical intelligence directly into the clinical workflow. This enables them to care for a significantly larger number of patients without compromising the quality of care, bringing scale, efficiency, and consistency to the front lines.

How ScopeAI Reimagines the Clinical Encounter

A ScopeAI-assisted visit involves a trained Medical Assistant (MA) meeting with a patient, guided by intelligent prompts from the ScopeAI system throughout the encounter. ScopeAI utilizes advanced clinical reasoning to actively listen to the patient, adapt its inquiries in real-time, and build a comprehensive understanding of the patient’s condition.

Leveraging sophisticated scribing and auditory capabilities, ScopeAI can engage in dynamic conversation while simultaneously generating a full clinical report. This report includes a preliminary diagnosis, a proposed treatment plan, and a detailed justification log for each decision made. This allows an Akido provider to oversee a team of MAs conducting ScopeAI visits, thereby increasing access to care while enabling the supervising provider to focus their expertise on higher-acuity or more complex cases. Providers gain a deeper, more complete picture of a patient’s health with less time spent on documentation.

Demonstrated Impact and Strategic Expansion Plans

Akido’s AI-based healthcare visits have already shown remarkable results, delivering five times more face-to-face time with patients and achieving an impressive 96 Net Promoter Score (NPS), indicating high patient satisfaction.

The new funding will accelerate the development and deployment of ScopeAI throughout Akido Care, Akido’s medical network which comprises 240 providers across 26 specialties in nearly 100 clinics. The investment will also support Akido’s expansion into new markets, including a recently announced first-of-its-kind healthcare program in New York City designed to address specific chronic diseases for professional rideshare and for-hire drivers.

Akido Background

Akido was founded in 2015 with the mission of reimagining healthcare for historically vulnerable communities by leveraging AI and machine learning. The launch of Akido Care in 2022 provided the real-world clinical environment and proprietary dataset of over 10 million patient case studies necessary to develop and refine ScopeAI through a reinforcement-loop-human-feedback (RLHF) environment. This continuous refinement by incorporating real-time provider feedback positions ScopeAI as one of the most sophisticated clinical AI systems available. By integrating ScopeAI into the Akido Care medical network, Akido is set to empower providers to deliver highly personalized care at an individual patient level while also scaling impactful health programs at a population level.